Effects of fucoidan and synbiotics supplementation during bismuth quadruple therapy of Helicobacter pylori infection on gut microbial homeostasis: an open-label, randomized clinical trial

作者：Huifen Wang, Wei Wei, Fang Liu, Miao Wang, Yanli Zhang, Shiyu Du · 发表于：Frontiers in Nutrition · 年份：2024 · DOI：10.3389/fnut.2024.1407736 · 被引用次数：10 · 研究领域：Helicobacter pylori-related gastroenterology studies、Microbial Metabolites in Food Biotechnology、Intestinal and Peritoneal Adhesions

Background The eradication regimen for Helicobacter pylori ( H. pylori ) infection can induce gut dysbiosis. In this open-label, prospective, and randomized clinical trial, we aimed to assess the effects of fucoidan supplementation on the eradication rate and gut microbial homeostasis in the context of quadruple therapy, as well as to investigate the combined effects of fucoidan and synbiotics supplementations. Methods Eighty patients with H. pylori infection were enrolled and randomly assigned to one of four treatment groups: the QT (a 2-week quadruple therapy alone), QF (quadruple therapy plus a 6-week fucoidan supplementation), QS (quadruple therapy plus a 6-week synbiotics supplementation), and QFS (quadruple therapy with a 6-week fucoidan and synbiotics supplementation), with 20 patients in each group. The QT regimen included rabeprazole, minocycline, amoxicillin, and bismuth potassium citrate. The synbiotics supplementation contained three strains of Bifidobacterium , three strains of Lactobacillus , along with three types of dietary fiber. All of the patients underwent 13 C-urea breath test ( 13 C-UBT) at baseline and at the end of the 6th week after the initiation of the interventions. Fresh fecal samples were collected at baseline and at the end of the 6th week for gut microbiota analysis via 16S rRNA gene sequencing. Results The eradication rates among the four groups showed no significant difference. In the QT group, a significant reduction in α-diversity of gut mi...